Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 5/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19871730 | 0.87 | MAPK14 (0.36) | SMN1; SMN2RAB9AARNAAAMAPK14 | |
| SCHEMBL24167762 | 0.85 | AR (0.43) | SMN1; SMN2NPC1MAPTRAB9AL3MBTL1 | |
| SCHEMBL16446744 | 0.81 | AR (0.41) | SMN1; SMN2NPC1MAPTRAB9AL3MBTL1 | |
| SCHEMBL454218 | 0.79 | AR (0.45) | SMN1; SMN2NPC1MAPTRAB9AL3MBTL1 | |
| SCHEMBL18053755 | 0.76 | GAA (0.41) | SMN1; SMN2MAPTL3MBTL1ARERN1 | |
| SCHEMBL453452 | 0.76 | AR (0.37) | SMN1; SMN2NPC1MAPTRAB9AL3MBTL1 | |
| SCHEMBL15655794 | 0.74 | AR (0.45) | SMN1; SMN2NPC1MAPTRAB9AL3MBTL1 | |
| SCHEMBL411745 | 0.74 | NPC1 (0.56) | SMN1; SMN2NPC1MAPTRAB9AL3MBTL1 | |
| SCHEMBL24586998 | 0.72 | L3MBTL1 (0.41) | SMN1; SMN2NPC1MAPTRAB9AL3MBTL1 | |
| SCHEMBL410179 | 0.71 | NPC1 (0.54) | SMN1; SMN2NPC1MAPTRAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4029870-A1 | TRICYCLIC BENZOXABOROLE COMPOUNDS AND USES THEREOF | GlaxoSmithKline Intellectual Property (No.2) Limited (GB) | 2022-07-20 | — | — | EP | disclosed |
| CN-110003253-B | Tricyclic benzoxaborole compounds and uses thereof | 葛兰素史克知识产权第二有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3030519-B1 | TRICYCLIC BENZOXABOROLE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-01-05 | — | — | EP | disclosed |
| EP-3030519-B1 | TRICYCLIC BENZOXABOROLE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-01-05 | — | — | EP | disclosed |
| US-20210053999-A1 | Tricyclic Benzoxaborole Compounds and Uses Thereof | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2021-02-25 | — | — | US | disclosed |
| US-10858376-B2 | Tricyclic benzoxaborole compounds and uses thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| US-20200095266-A1 | Tricyclic Benzoxaborole Compounds and Uses Thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2020-03-26 | — | — | US | disclosed |
| US-20190241586-A1 | Tricyclic Benzoxaborole Compounds and Uses Thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
| US-20190241586-A1 | Tricyclic Benzoxaborole Compounds and Uses Thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-08-08 | — | — | US | disclosed |
| US-10308668-B2 | Tricyclic benzoxaborole compounds and uses thereof | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2019-06-04 | — | — | US | disclosed |
| US-20180044355-A1 | TRICYCLIC BENZOXABOROLE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-02-15 | — | — | US | disclosed |
| US-20180037595-A1 | BENZOXABOROLE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-02-08 | — | — | US | disclosed |
| EP-3256480-A1 | BENZOXABOROLE COMPOUNDS AND USES THEREOF | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2017-12-20 | — | — | EP | disclosed |
| US-20160251380-A1 | TRICYCLIC BENZOXABOROLE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-09-01 | — | — | US | disclosed |
| WO-2016128949-A1 | BENZOXABOROLE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-08-18 | — | — | WO | disclosed |
| EP-3030519-A2 | TRICYCLIC BENZOXABOROLE COMPOUNDS AND USES THEREOF | Glaxosmithkline Intellectual Property (No. 2) Limited (GB) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015021396-A9 | TRICYCLIC BENZOXABOROLE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-02-11 | — | — | WO | disclosed |
| WO-2015021396-A2 | TRICYCLIC BENZOXABOROLE COMPOUNDS AND USES THEREOF | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241586-A1 | Tricyclic Benzoxaborole Compounds and Uses Thereof | CBX2, BRD4, BRD3 | SMN1; SMN2 3891/4885NPC1 1618/4885MAPT 4191/4885 |
| US-20210053999-A1 | Tricyclic Benzoxaborole Compounds and Uses Thereof | CBX2, BRD4, BRD3 | SMN1; SMN2 3891/4885NPC1 1618/4885MAPT 4191/4885 |
| US-20160251380-A1 | TRICYCLIC BENZOXABOROLE COMPOUNDS AND USES THEREOF | CBX2, BRD4, BRD3 | SMN1; SMN2 3891/4885NPC1 1618/4885MAPT 4191/4885 |
| US-20180037595-A1 | BENZOXABOROLE COMPOUNDS AND USES THEREOF | BRD3, BRPF3, BRD4 | SMN1; SMN2 3699/4885NPC1 1715/4885MAPT 4479/4885 |
| US-20200095266-A1 | Tricyclic Benzoxaborole Compounds and Uses Thereof | CBX2, BRD4, BRD3 | SMN1; SMN2 3891/4885NPC1 1618/4885MAPT 4191/4885 |
| US-20180044355-A1 | TRICYCLIC BENZOXABOROLE COMPOUNDS AND USES THEREOF | CBX2, BRD4, BRD3 | SMN1; SMN2 3891/4885NPC1 1618/4885MAPT 4191/4885 |
| US-10858376-B2 | Tricyclic benzoxaborole compounds and uses thereof | CBX2, BRD4, BRD3 | SMN1; SMN2 3891/4885NPC1 1618/4885MAPT 4191/4885 |
| US-10308668-B2 | Tricyclic benzoxaborole compounds and uses thereof | CBX2, BRD4, BRD3 | SMN1; SMN2 3891/4885NPC1 1618/4885MAPT 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.